Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | NMT2 | O60551 | 7/20 | 0.39 |
| ▸ | NMT1 | P30419 | 7/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.39 |
| ▸ | EDNRA | P25101 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3610784 | 0.89 | NPC1 (0.45) | NPC1RAB9AMAPTKDM4EHSD17B10 | |
| SCHEMBL3609756 | 0.88 | NMT2 (0.42) | NPC1RAB9AMAPTKDM4EHSD17B10 | |
| SCHEMBL3619431 | 0.82 | MMP2 (0.45) | NPC1RAB9AMAPTKDM4EHSD17B10 | |
| SCHEMBL3615778 | 0.82 | EDNRA (0.54) | NPC1RAB9AMAPTKDM4EHSD17B10 | |
| SCHEMBL3611948 | 0.78 | NPC1 (0.68) | NPC1RAB9AMAPTKDM4EHSD17B10 | |
| SCHEMBL3616063 | 0.78 | NR3C2 (0.45) | NPC1RAB9AMAPTLMNAMAPK1 | |
| SCHEMBL23532130 | 0.77 | NPC1 (0.48) | NPC1RAB9AMAPTKDM4EHSD17B10 | |
| SCHEMBL3602060 | 0.76 | EDNRA (0.68) | NPC1RAB9AMAPTKDM4EHSD17B10 | |
| SCHEMBL3615714 | 0.72 | NMT2 (0.50) | NPC1RAB9AMAPTKDM4EHSD17B10 | |
| SCHEMBL3620721 | 0.71 | NMT2 (0.58) | NMT2NMT1EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | WYETH (US) | 2010-06-03 | — | — | US | disclosed |
| EP-1692124-B1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH CORP (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7420001-B2 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1692124-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | Wyeth (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005061477-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| CN-1623537-A | Biaryl sulfonamides and its using method | WYETH CORP (US) | 2005-06-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | STS, MMP3, AADAC | NPC1 2605/4885RAB9A 3864/4885MAPT 4416/4885 |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | STS, MMP3, AADAC | NPC1 2605/4885RAB9A 3864/4885MAPT 4416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.